Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to con...

por Strand, Vibeke, de Vlam, Kurt, Covarrubias-Cobos, Jose A, Mease, Philip J, Gladman, Dafna D, Graham, Daniela, Wang, Cunshan, Cappelleri, Joseph C, Hendrikx, Thijs, Hsu, Ming-Ann
Publicado 2019

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, ran...

por Strand, Vibeke, de Vlam, Kurt, Covarrubias-Cobos, Jose A, Mease, Philip J, Gladman, Dafna D, Chen, Linda, Kudlacz, Elizabeth, Wu, Joseph, Cappelleri, Joseph C, Hendrikx, Thijs, Hsu, Ming-Ann
Publicado 2019

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

por Nash, Peter, Coates, Laura C., Kivitz, Alan J., Mease, Philip J., Gladman, Dafna D., Covarrubias-Cobos, José A., FitzGerald, Oliver, Fleishaker, Dona, Wang, Cunshan, Wu, Joseph, Hsu, Ming-Ann, Menon, Sujatha, Fallon, Lara, Romero, Ana Belén, Kanik, Keith S.
Publicado 2020